Rigel Pharmaceuticals Inc expected to post a loss of 3 cents a share - Earnings Preview

Rigel Pharmaceuticals

04/05/2024 03:11

* Rigel Pharmaceuticals Inc  RIGL.OQ   RIGL.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 7
for the period ending March 31 2024
    * The South San Francisco California-based  company is
expected to
report a 20.0% increase in revenue to $31.284 million from
$26.07 million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Rigel Pharmaceuticals
Inc is
for a loss of 3 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2.50​, above​ its last closing price
of $1.20. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.03       -0.03      0.00      Beat    100
 Sep. 30 2023  -0.07       -0.07      -0.03     Beat    57.7
 Jun. 30 2023  -0.08       -0.08      -0.04     Beat    48.7​
 Mar. 31 2023  -0.09       -0.10      -0.08     Beat    17.9
 ​​Dec.        -0.11       -0.11      0.01      Beat    108.9
 31 2022                                                
 Sep. 30 2022  -0.13       -0.13      -0.11     Beat    18.2​
 Jun. 30 2022  -0.13       -0.12      -0.08     Beat    34.8
 Jan. 1 0001   -0.14       -0.14      -0.16     Missed  -16.5
 This summary was machine generated May 4 at 02:11 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)